Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Incyte Corp. has disclosed GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, as well as autoimmune and inflammatory disorders.

Chengdu Easton Biopharmaceuticals Co. Ltd. has described menin (MEN1)/KMT2A (MLL) interaction inhibitors reported to be useful for the treatment of cancer and diabetes.

Chiesi Farmaceutici SpA has divulged sodium channel protein type 9 subunit α (Nav1.7) channel blockers reported to be useful for the treatment of chronic cough.

Scientists at Bayer AG and Dana Farber Cancer Institute Inc. have identified EGFR (exon 20 insertion [Ex20Ins] mutant) and/or HER2 (erbB2) (Ex20Ins mutant) inhibitors reported to be useful for the treatment of lung cancer.

Scientists at Ascentage Pharma (Suzhou) Co. Ltd. and China Pharmaceutical University have synthesized molecular glue degrader compounds acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)/CRBN interaction inducers for GSPT1 degradation reported to be useful for the treatment of cancer, viral infections, aging, immunological disorders and neurological disorders.

Aurigene Oncology has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase protein binding moiety covalently linked to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) binding moieties through a linker.

Esperion Therapeutics Inc. has described ATP citrate lyase (ACLY) inhibitors reported to be useful for the treatment of cancer, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), type 2 diabetes, chronic kidney disease, autoimmune disease and inflammatory disorders.

Evommune Inc. has divulged protein kinase PKCθ inhibitors reported to be useful for the treatment of Crohn’s disease and ulcerative colitis.

Merck Sharp & Dohme LLC has identified receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, multiple sclerosis, stroke, Alzheimer’s disease and Parkinson’s disease, among others.